Abstract：
While conventional in-office phototherapy has long been utilized as a successful treatment for atopic dermatitis (AD), it is associated with potential barriers including inconvenience, poor adherence, time and financial expense. In this retrospective study, we examine the efficacy, adherence, and patient-satisfaction of using adjunctive at-home, self-administered phototherapy utilizing a novel handheld narrow-band ultraviolet B (NB-UVB) device for the treatment of refractory mild to severe AD. Included AD patients were initially trained on proper use of the device. These patients treated involved areas three times per week for a period of 12 weeks. Phototherapy dosing protocol was based on skin type. The cohort included 52 patients, who were aged 20-69 and represented all skin types. They were initially categorized by disease involvement as mild, moderate, and severe. Patients were also queried to self-score their disease severity and level of satisfaction. Compared to baseline, at 12 weeks, 48% percent of patients indicated that at least one site was Clear/Almost Clear, 38% stated that more than 50% of body locations were Clear/Almost Clear, and 28% reported that 100% (all) treated sites were Clear/Almost Clear. After using at-home hand-held NB-UVB for the study duration, 67% (35/52) of patients experienced disease improvement. Mean overall satisfaction was extremely high at 4.43 on a 5-point scale. Skin type, age, gender, and disease severity at inception did not significantly affect patient satisfaction scores. Overall adherence rate among participants across all groups was 73%. In this small retrospective study, at-home handheld NB-UVB phototherapy was found to be an effective, well-tolerated, adjunctive treatment method for patients with refractory AD, which was associated with a high level of patient satisfaction and adherence.
摘要：
虽然传统的办公室光疗长期以来一直被用作特应性皮炎（AD）的成功治疗方法，它与潜在的障碍有关，包括不便，依从性差，时间和财务费用。在这项回顾性研究中,我们检查功效，坚持,以及患者对在家使用辅助药物的满意度，使用新型手持式窄带紫外线B（NB-UVB）设备进行自我施用的光疗，用于治疗难治性轻度至重度AD。包括的AD患者最初接受了正确使用设备的培训。这些患者每周治疗3次，持续12周。光疗给药方案基于皮肤类型。该队列包括52名患者，年龄在20-69岁之间，代表所有皮肤类型。他们最初被归类为轻微的疾病参与，中度,和严重。还询问患者对其疾病严重程度和满意度进行自我评分。与基线相比，在12周，48%的患者表示至少有一个部位是清晰/几乎清晰的，38%的人表示，超过50%的身体位置是清晰/几乎清晰的，28%的人报告100%(所有)治疗部位为透明/几乎透明。在研究期间使用家庭手持NB-UVB后，67%(35/52)的患者经历了疾病好转。5分制的平均总体满意度极高，为4.43。皮肤类型,年龄,性别,开始时的疾病严重程度对患者满意度评分无显著影响.所有组参与者的总体依从率为73%。在这项小型回顾性研究中，家用手持NB-UVB光疗被发现是一种有效的，耐受性良好,难治性AD患者的辅助治疗方法,这与高水平的患者满意度和依从性相关。
